Channel
@pantini_biopharm
On this record: Topic · Growth · Engagement · Posts · Cite this entry
754subscribers
-4 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1001278029933 |
|---|---|
| Type | Channel |
| Username | @pantini_biopharm |
| Created | Between 1 March 2018 and 31 July 2021 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 6 August 2026 |
| Last confirmed live | 15 September 2026 |
| Measurements held | 5 |
| Confirmed unchanged | 1 time, most recently 15 September 2026 |
| On Telegram | t.me/pantini_biopharm |
Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 20 September 2026 and assigned it the closest of 31 fixed categories, at 51% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 15 Sept 2026, 02:16 | 754 | -2 |
| 22 Aug 2026, 17:14 | 756 | -4 |
| 14 Aug 2026, 17:47 | 760 | +2 |
| 7 Aug 2026, 10:25 | 758 | no change |
| 6 Aug 2026, 21:16 | 758 | first reading |
20 posts held, back to 2 March 2022 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 2 March 2022. An engagement rate over an empty window would be a number about nothing.
$HOOK (2.52$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced...
$JNCE (7.35$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results - Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 - - JTX-1484, a new antagonist antibody targeting LILRB4, enters...
$ALXO (18.14$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company"), a clinical-stage immuno-oncology company developing therapies t…
🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK BioIntelliSense and UAE-based Mubadala Health Establish Strategic Collaboration to Enable Continuous Care Model for Medical Grade Remote Monitoring and Management DENVER and ABU DHABI, United Arab Emirates, March 02, 2022 (GLOBE NEWSWIRE) -- BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, announced today its strategic collaboration with..
$ARFXF (0.09948$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK ProMIS Neurosciences' PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer's disease TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...
$EVLO (3$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments...
$QURE (17.48$) $CRBP (0.32$) $AKTX (1.36$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:02 MSK Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...
$KZR (14.57$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:02 MSK Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig,...
$TCRX (4.22$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK TScan Therapeutics to Participate in Upcoming Investor Conferences WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the...
🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:03 MSK BlueWillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal COVID-19 Booster Candidate in Pre-clinical Studies BW-1019 elicits mucosal immunity, stopping spread at the entry of the virus Intranasal booster following primary intramuscular vaccine series shown to be a successful follow-on solution BlueWillow Biologics, Inc., a...
$KMDA (5.75$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:02 MSK Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022 REHOVOT, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and...
$AXSM (30.98$) 🇺🇸 🕒 ср, 2 мар. 2022 г., 15:00:02 MSK Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced...
Showing the 12 most recent of 20 posts we hold for @pantini_biopharm. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 15 September 2026 — this entry's latest reading, not the date you are reading this.
“Pantini Biopharm” (@pantini_biopharm), 754 subscribers as measured 15 September 2026. Telegram Register, tgregister.com/channel/pantini_biopharm.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.